WHAT IS THE CADTH REIMBURSEMENT RECOMMENDATION FOR SOTYKTU?: CADTH recommends that Sotyktu not be reimbursed by public drug plans for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. WHY DID CADTH MAKE THIS RECOMMENDATION? The evidence from 2 clinical trials was insufficient to determine that Sotyktu offered treatment benefits over the currently available advanced treatments in Canada for the treatment of moderate to severe plaque psoriasis in adults. No evidence was found that directly compared Sotyktu to newer interleukin (IL)-17 and IL-23 biologics, and the indirect evidence suggested that Sotyktu was less effective at improving skin plaques than several biologics (including IL-17 and IL-23 biologics) that are available and reimbursed in Canada. CADTH concluded that there was not enough evidence to show that Sotyktu met the needs of patients with moderate to severe plaque psoriasis not already addressed by other available treatments.
WHAT IS PLAQUE PSORIASIS? Plaque psoriasis is a skin disease that causes red, flaky, crusty patches of skin that may be itchy and painful and can lead to negative impacts on social and work life. Up to 1 million people in Canada are living with psoriasis, a third of whom have moderate to severe disease. UNMET NEEDS IN PLAQUE PSORIASIS: Although many treatments are approved in Canada for moderate to severe plaque psoriasis, some patients may not respond to these treatments. Other treatment options are needed for these patients. HOW MUCH DOES SOTYKTU COST? Treatment with Sotyktu is expected to cost $14,409 per patient per year.
